Choosing a cell intervention: match the exact product to the exact evidence
Broad rules such as “MSC for joints” or “neural cells for neurological disease” are not clinical evidence. Product, indication, dose, route and regulatory status must match.
Begin with a confirmed diagnosis, disease stage, current treatment, alternatives and a defined clinical goal. A cell type should not be selected from a marketing category. The relevant question is whether an exact, characterised product has credible evidence and a lawful pathway for a specified population and indication.
Build a product identity record: source tissue, autologous or allogeneic status, manipulation, culture and passage where applicable, formulation, dose, route, schedule, manufacturer, release tests and proposed mechanism. MSCs from different tissues and processes are not one product; neither are neural-cell preparations or exosome products.
Then build an evidence matrix. The study population, product, dose, route, comparator and endpoints must match the proposal. Laboratory differentiation, animal repair, anti-inflammatory signalling or a study in another disease can support a hypothesis but cannot establish clinical benefit. Do not infer rapid effects for exosomes or tissue replacement from a cell label.
Check regulation separately. Ask for the exact marketing authorisation, authorised clinical-trial identifier or national-authority exemption for the product and site. A tissue-establishment licence, GMP certificate, ethics opinion or registry listing addresses different questions and does not make a product effective or authorised for every use.
Have an independent specialist compare the proposal with established options and registered trials. Use the ISCT MSC nomenclature statement, EMA ATMP overview and ISSCR patient guide. If the provider cannot connect every claim to the same product and indication, the match has not been demonstrated.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.